Fusion Antibodies are pleased to be attending Antibody Engineering & Therapeutics Asia on 26-28th February 2019 in Tokyo.

Taking place at the Hilton Tokyo Bay Hotel, Tokyo, Japan on 26-28th February 2019,  Antibody Engineering & Therapeutics Asia is the only event in Asia providing the latest science, technology and partners to accelerate antibody and  protein therapies, ADCs, Bispecifics and immune-oncology. The event plays host to world-renowned scientists sharing the latest technologies, R&D and clinical data to fast track your next-generation therapeutics towards commercial success, so it is an event not to be missed!

Get in touch with us to organise a meeting with our CEO Paul Kerr and our Business Development Executive Yang Yang , tell us about your projects needs and hear all about how Fusion Antibodies pioneering services can help you.

Fusion Antibodies is pleased to introduce our unique Antibody Developability by Design platform or ADD™.

Our  ADD™ platform helps advance novel biologics through clinical development and to the market.

Here at Fusion Antibodies, our team can assess and optimize the developability profile of your antibody at the earliest stages to deliver the best possible antibody sequence. With years of experience in antibody engineering and manufacturing cell line development, Fusion Antibodies understands what it takes to deliver the optimal antibody sequence. 

Our platform provides cost-effective solutions to mitigate risk throughout your antibody development program, offering the best chances of success in the clinic.

Read more about our unique ADD™ platform here or email us at info@fusionantibodies.com today and speak with one of our team about how we can help with your individual project.

We begin with the end in mind.

Fusion Antibodies will be attending the following events in the first half of 2018. If you are going to be at any of the following events with us today via email at info@fusionantibodies.com and arrange a meeting!

Bio-Europe Spring – 12-14th March – Amsterdam

With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “who’s who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.

Fusion Antibodies Paul Kerr (CEO) and Hayley Close (Business Development) will be attending this event, so get in contact today to organise a meeting!

US Antibody Engineering Strategy Meeting – 13th March – Philadelphia

HubXchange’s US Antibody Engineering Strategy Meeting 2018, bringing together executives from pharma and biotech as well as thought leaders from academia to address and find solutions to the key issues faced in engineering antibodies.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Fusion Antibodies Julie Gormley (Senior Business Development) and Hugh Morgan (Antibody Purification and Analytics Scientist) will be attending this event and hosting a roundtable as well as holding one-to-one meetings, so get in touch today to organise a meeting.

PEGS Boston – 30th April – 4th May — Boston – Visit us at booth 616

PEGS: The Essential Protein Engineering Summit is one of the industry’s most preeminent events that inspires accelerated biotherapeutic protein drug development. This weeklong event attracts over 2,300 international participants and features nearly 400 presentations by world-renowned leaders from pharma, academia, and government showcasing case studies, cutting-edge data, insight and perspective. Conference programs include a broad spectrum of topics including protein and antibody engineering, cancer immunotherapy, oncology, and emerging therapeutics.

AACR Annual Meeting – 14-18th April – Chicago – Visit us at booth 1449

Founded on May 7, 1907, the AACR is the first and largest professional organization in the world dedicated to advancing cancer research and its mission to prevent and cure all cancers. The theme for the upcoming Annual AACR Meeting is “Driving Innovative Cancer Science to Patient Care.” This theme is a powerful reminder that at the heart of every scientific advance is a patient in urgent need of a cure.

 Fusion Antibodies Julie Gormley (Senior Business Development) and Jody Haddow (Business Development) will be attending this event, so get in touch today to organise a meeting.

Bio 2018 – 4-7th June – Boston

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and in more than 30 other nations.

Attending the 2018 BIO International Convention gives you access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.

Fusion Antibodies introduces novel Affinity Maturation platform (RAMP™)

Building upon over 18 years’ experience in antibody engineering and humanization we are proud to introduce our novel Affinity Maturation platform (RAMP™) for the rapid optimization of your antibody.

Somatic hypermutation is the natural process by which immunoglobulins undergo affinity maturation and selection, as part of the adaptive immune response, in order to increase their binding affinity to their target antigen

Fusion Antibodies’ RAMP™ platform adopts lessons from nature and combines a rational approach to library design, with rapid in silico selection for both improved binding potential and predicted stability. The result is that we will generate an enriched ‘micro-library’ of variants with improved stability and affinity for the target.

We go the extra mile to deliver exceptional antibodies by applying our expert knowledge and cutting edge technologies. Our RAMP™ platform is designed to accelerate your lead selection program, providing you with the best chances of success in the clinic.

For more information on our Affinity Maturation service (RAMP™) read more here or contact us today!

Ground Breaking New Saliva Diagnostic Test Set to Help Eliminate Malaria

ERADA Technology Alliance Ltd (ERADA), pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.

The saliva-based diagnostic tool, to be marketed by ERADA as a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART) for sub-clinical infection, is set to transform malaria detection worldwide in the fight against one of the globe’s most deadly diseases. Malaria, globally kills an estimated 435,000 each year, mostly children under the age of five, mainly in Sub-Saharan Africa. 1 

The SMAART detection tool is the invention of leading, U.S based, researchers in the field of malaria diagnostics whose study is published worldwide today, January 2 in the international journal, Science Translational Medicine

ERADA’s innovative solution is easy- to-use, as it includes a simple device for standardized collection of saliva that can be implemented in the community by health care professionals, teachers and parents; contrasting with invasive blood tests, which must be administered by trained clinicians. Other drawbacks to blood tests include cultural ‘blood taboos’ existing in many countries whilst, furthermore, skin-prick tests are often stressful for children and parents. 

Existing tests using blood may be invariably less reliable because sub-clinical infections with malaria-carrying parasites can be missed, leading some patients to come down with the disease, without knowing they have already been infected.

ERADA’s SMAART-1, easy-to-use saliva test, leads to early detection, treatment and prevention of the disease as well as reducing further transmission of malaria.

ERADA’s SMAART saliva test detects a unique bio-marker from female parasites circulating in an infected human who is asymptomatic, but is carrying the parasite and likely to come down with malaria within a week. Early, sub-clinical detection of malaria is crucial to malaria eradication because individuals who carry the parasite without exhibiting symptoms, known as carriers, are the reservoir that leads to infection of mosquitoes and transmission of the disease. Detecting the presence of the parasite before symptoms appear can save lives because malaria visible disease only erupts a couple of days after the mosquito bite.

The SMAART detection tool works by detecting a novel bio-marker for Plasmodium falciparum parasites. In some areas of the world, the parasites have acquired a mutation and are therefore no longer detected by current blood-based tests. But ERADA’s saliva test detects an essential protein the parasite needs for survival, which should avoid the problem of influence from the mutation and keep the test effective long-term.

 “As someone who has suffered from malaria, I know first-hand that if the parasite had been detected early, I could have been treated and cured before the symptoms of the disease made me unwell,” Dr Benji Pretorius, ERADA’s founder and Managing Director says.”

Dr Pretorius continues, “As a practicing clinician myself and following my personal experience of this debilitating disease, I was spurred on to work with my colleague Dr Richard Schmidt in our small community, Musina, in South Africa, together with a global team of scientists.” Dr Pretorius continues, “Our vision is to bring to market ERADA’s SMAART diagnostic tool as quickly as possible in the belief that it will go on to save literally millions of lives in the future.”

The World Health Organization’s recently published World Malaria Report 2018 reinforces the message that the world is currently behind 2020 milestones of the WHO Global Technical Strategy for Malaria 2016–2030. 1Reduction in malaria cases has stalled and of particular concern is the report’s finding that, in 2017, there were an estimated 3.5 million more cases of malaria in the 10 highest burden African countries. 1,3 

“The introduction of SMAART is going to play a major part in achieving effective diagnostic testing and surveillance; as well as prevention and treatment of this disease, and therefore will be a major catalyst in meeting the WHO’s 2030 target to reduce malaria incidence and mortality by 90% ,” Dr Pretorius says. 2 

Research and development of this new saliva test was assisted with funding from the Bill & Melinda Gates Foundation in 2014. This was augmented by the technical expertise of Maryland Innovation Initiative and the Dinglasan Malaria laboratory. This world-first patented technology is licensed exclusively to ERADA Technology Alliance Ltd by Johns Hopkins University and ERADA will bring this innovative diagnostic tool to market in partnership with the Dinglasan Malaria Laboratory based at the University of Florida, U.S;Oasis Diagnostics® Corporation, a U.S based oral diagnostic testing company; Fusion Antibodies in the UK and Synergyworx International Holdings, an international investee company with strong humanitarian health interests in Africa.

For more information, contact Joanna Scott at pressoffice@eradatechnology.com or visit www.eradatechnology.com

 References

  1. World malaria report. Geneva: World Health Organization; 2018: Available athttps://www.who.int/malaria/publications/world-malaria-report-2018/en/
  2. Global Technical Strategy for Malaria, 2016-2030. Geneva: World Health Organization; 2015: Available at https://www.who.int/malaria/publications/atoz/9789241564991/en/
  3. https://www.who.int/news-room/detail/19-11-2018-who-and-partners-launch-new-country-led-response-to-put-stalled-malaria-control-efforts-back-on-track

About ERADA Technology Alliance Ltd (ERADA)

ERADA Technology Alliance Ltd (ERADA), was founded by Dr Benji Pretorius and Dr Richard Schmidt, located in Musina, South Africa, and pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, including malaria.  Dr Pretorius, the company’s Managing Director, himself an experienced medical practitioner, is an expert in the field of malaria management and has a long track record of working in the pharmaceutical, health, wellness and fitness industry. 

Fusion Antibodies and Analytics Engines to incorporate artificial intelligence into its world class antibody humanization service.

Fusion Antibodies plc, experts in antibody engineering and Analytics Engines, an advanced data analytics company, have announced a strategic collaboration to incorporate machine learning (ML) and artificial intelligence (AI) into Fusion Antibodies’ CDRx™ humanization platform. This collaboration will boost Fusion Antibodies’ continual efforts to improve its algorithms to understand the structure/function relationship of its target antibodies. The CDRx™ platform makes it possible to perform multiple virtual experiments with panels of selected antibodies to discover properties that meet desired functionality and developability requirements with the long-term goal of reducing development costs and accelerating timelines so that novel antibody drugs can reach patients faster. 

“We are delighted to have the opportunity to collaborate with the team at Analytics Engines to incorporate artificial intelligence into our CDRx™ platform. At Fusion Antibodies we want to keep differentiating our product to make sure it’s the best humanization platform in the world, and that’s our goal, keeping ourselves in front. Collaborating with Analytics Engines will allow us to drive up our quality and add more certainty and manufacturability to the products,” said Paul Kerr, CEO of Fusion Antibodies. 

“Analytics Engines are excited to be part of this collaboration, assisting Fusion Antibodies in taking the CDRx platform to the next level. Using our expertise in Machine Learning and AI, Fusion Antibodies will be able to create ML models to continually improve their antibody humanization process” said Aislinn Rice, CEO of Analytics Engines.

About Analytics Engines

Analytics Engines is a global leader in the delivery and implementation of advanced Data Analytics Solutions.  Headquartered in Belfast, Analytics Engines employs 20 people with expertise in data infrastructure, data engineering, artificial intelligence and machine learning, data analytics and visualizations.

Analytics Engines technology and expertise enables organisations to convert data into valuable business insights. We have developed a range of high-value solutions within the healthcare, government and private sectors. Built upon the Analytics Engines XDP™ data platform, the company has also developed a range of products for smart cities, healthcare, and governmental bodies.

To find out how Analytics Engines can help you gain value from you data visit us at – www.analyticsengines.com

Read more here or contact us today!